A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Basic Clin Androl
Main Authors: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://ncbi.nlm.nih.gov/pubmed/30026950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12610-018-0074-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados